Best Pharma Manufacturing Podcasts (2024)

1
Pharma’s new age of longevity 4:15

7h ago4:15

4:15

The concept of healthspan has recently gained new attention in the pharma industry and rightfully so, given the surprisingly large chasm in the U.S. between average years lived (77.5) and average years lived in good health (63.9). Facing a growing demographic of unhealthy seniors, a handful of innovative biotechs are reframing the longevity discuss…

1
Quick Hits: Opportunities in School-Based Healthcare Services in the United States 7:06

4h ago7:06

7:06

Cain Brothers’ Director Jenny Watson talks about the massive need for school-based healthcare services including dental care, primary care, and behavioral health. Cain Brothers is a division of KeyBanc Capital Markets.By Cain Brothers, a division of KeyBanc Capital Markets

1
Non-Hormonal Innovations in Obesity and Diabetes Treatment with Aphaia Pharma’s Dr. Steffen-Sebastian Bolz 42:30

1h ago42:30

42:30

In this episode, Ayesha spoke with Steffen-Sebastian Bolz, MD, PhD, a scientist, physician and entrepreneur. He is a Co-Founder of Aphaia Pharma AG and Founder and Chief Scientific and Medical Officer at Qanatpharma AG. Dr. Bolz holds a full professorship at the University of Toronto, is a Principal Investigator at the Ted Rogers Centre for Heart R…

1
E128 | Leveraging AI for Early Disease Prediction 32:11

3h ago32:11

32:11

In this episode of AI For Pharma Growth, Dr. Andree Bates is joined by Xander Kerman Gregory, the Head of Growth at Ubie Health, to discuss the company's innovative work in early disease prediction through the power of artificial intelligence. Ubie Health focussed on user-centric design to dynamically guide patients through a series of carefully se…

1
Emergent donates 50k doses of mpox vaccine to Africa, FDA rejects Regeneron blood cancer bispecific antibody, China indicts Astellas exec for espionage [The good, the bad, the ugly] 3:41

7h ago3:41

3:41

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Emergent donates 50,000 doses of mpox vaccine to Africa The bad — FDA rejects Regeneron blood cancer bispecific antibody The ugly — China indicts Astellas exec for espionage…

1
Quick Hits: Current Challenges & Trends Impacting the Medical Manufacturing Market 8:05

2h ago8:05

8:05

In this Quick Hits House Call, Dave talks to Cain Brothers’ Managing Director Carl Hardie about the outsourced medical manufacturing market’s “crazy ride”, how industry leaders are navigating a host of operating challenges, and why the sector is stronger than ever and continues to grow. Cain Brothers is a division of KeyBanc Capital Markets.…

1
FNIH Study Shows Promise of Blood Tests for Alzheimer’s Disease, featuring Dementia Expert Dr. Schindler and FNIH Neuroscience Director Dr. Travaglia 36:43

7d ago36:43

36:43

In this episode, Ayesha spoke with Alessio Travaglia, PhD, neuroscientist and Director Neuroscience at the Foundation for the National Institutes of Health (FNIH) and Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University. Results from a head-to-head study led by the FNIH Biomarkers Consortium, with data analysis led …

1
E127 | Who is using your face? Find out with AI 26:56

1h ago26:56

26:56

In this episode of AI For Pharma Growth, Dr. Andree Bates is joined by IdentifAI founders Justin Marciano and Paul Vann to explore the deep fake challenge and the innovative solutions they are developing. The pair share their unique backgrounds and motivations for founding the company, emphasising the critical need to address the growing threat of …

1
FDA approves Ascendis drug, Lykos PTSD treatment rejected, Novartis bid blocked [The good, the bad, the ugly] 3:21

22h ago3:21

3:21

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Ascendis hypoparathyroidism drug The bad — FDA rejects Lykos MDMA PTSD drug The ugly — Judge blocks Novartis bid to stop generic blockbuster heart drug…

1
Quick Hits: Medicare Redo or Delay? 12:31

3h ago12:31

12:31

In this Quick Hits House Call, Dave talks to Cain Brothers’ Managing Director Mike Elizondo about tumult in the Medicare Advantage market and why this could be an historic opportunity for health plans to drive growth. Cain Brothers is a division of KeyBanc Capital Markets.By Cain Brothers, a division of KeyBanc Capital Markets

1
Beyond the Beat: Dr. Matthew Martinez Discusses HCM Care in Athletes and New Camzyos Guidelines 39:15

13d ago39:15

39:15

In this episode, Ayesha spoke with Matthew Martinez, MD, a board-certified cardiologist and nationally recognized expert in hypertrophic cardiomyopathy (HCM). He serves as director of Atlantic Health System Sports Cardiology and the director of the Chanin T. Mast Center for Hypertrophic Cardiomyopathy. Dr. Martinez is the Chair of ACC online “LEARN…

1
E126 | The impact of RAG and LLMs on data processing and decision-making 25:51

16d ago25:51

25:51

In this episode of AI For Pharma Growth, Dr. Andree Bates is joined by Vinoth Nageshwaran, a leading data engineer currently working at Business Insider. Vinoth discusses the challenges of large language models (LLMs) like ChatGPT, which often hallucinate or generate inaccurate information due to their lack of true understanding and ability to veri…

1
Amneal's Parkinson's pill approved, Novo Nordisk withdraws Wegovy approval expansion bid, FDA delays BeiGene Tevimbra decision [The good, the bad, the ugly] 2:59

8d ago2:59

2:59

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Amneal gets FDA nod for Parkinson’s pill The bad — Novo Nordisk withdraws bid for Wegovy label expansion in heart failure The ugly — FDA delays decision on BeiGene Tevimbra as a first-line therapy…

1
Bridging Science and Advocacy with Lawreen Asuncion, Life Science Professional and Rare Disease Patient Advocate 33:48

9d ago33:48

33:48

In this episode, Ayesha spoke with Lawreen Asuncion, a patient advocate who works to raise awareness for the rare disease Usher syndrome. Lawreen has worked professionally in the biotech and life science markets for over 25 years. She provides input and perspectives for rare genetic disease programs and clinical trials sponsored by biotech and phar…

1
E125 | Using AI to power early detection and provide better treatments in oncology and cardiovascular care 23:20

21d ago23:20

23:20

In this episode of AI For Pharma Growth, Dr. Andree Bates is joined by Navid Alipour, CEO of CureMetrix, which is a leading AI-powered medical imaging company that specialises in early detection of breast cancer and heart disease. The company has received two historic FDA clearances for its AI-powered breast cancer detection and breast arterial cal…

1
FDA approves Adaptimmune therapy, halts vTv diabetes program; Sanofi sues Sarepta over Duchenne patents [The good, the bad, the ugly] 3:58

23d ago3:58

3:58

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Adaptimmune engineered cell therapy The bad — FDA puts clinical hold on vTv Therapeutics diabetes program The ugly — Sanofi sues Sarepta over manufacturing patents for Duchenne gene ther…

1
The Impact of Digital Twins on Airport Operations 17:45

10d ago17:45

17:45

Philippe Delannoy, Director, Building Equipment at Dassault Systèmes, chats with Bill Hoffman, Chairman & CEO of Object Management Group, about how digital twins are driving efficiencies in airport operations, one of the most challenging ecosystems to manage. Visit us at https://www.digitaltwinconsortium.org/…

1
Bringing Integrated Nutritional and Pharmaceutical Approaches to the Table for GI Health with Nestlé Health Science’s Moreno Perugini 36:26

23d ago36:26

36:26

In this episode, Ayesha spoke with Moreno Perugini, President of Active & Medical Nutrition, US & President of Global Pharmaceutical Therapies at Nestlé Health Science US. As President of Global Pharmaceutical Therapies, Moreno and his team actively shape the healthcare system through innovative approaches and a strong commitment to delivering phar…

1
E124 | How AI is being used to tackle global health challenges 29:58

14d ago29:58

29:58

In this episode of AI For Pharma Growth, Dr. Andree Bates is joined by Julien Willard, a Partner and Life Science Lead at IBM. Julien is focused on how AI is being used to tackle global health challenges, particularly in low and middle-income countries (LMICs). Julien & Andree discuss the importance of accounting for local context when implementing…

1
FDA approves Sun Pharma hair loss drug, FDA issues warning letter to Brassica, EMA rejects Eisai-Biogen Alzheimer's drug [The good, the bad, the ugly] 3:46

29d ago3:46

3:46

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Sun Pharma hair loss drug The bad — FDA issues harsh warning letter to Indian CDMO Brassica The ugly — EMA issues negative opinion on Eisai-Biogen Alzheimer's drug…

1
Innovating Approaches to Target Diseases of Aging with Jerry McLaughlin, CEO of Life Biosciences 29:30

1M ago29:30

29:30

In this episode, Ayesha spoke with Jerry McLaughlin, chief executive officer and board member of Life Biosciences, a company advancing innovative cellular rejuvenation platforms to reverse diseases of aging. Life Biosciences is developing a gene therapy for primary open-angle glaucoma (POAG) and non-arteritic anterior ischemic optic neuropathy (NAI…

1
E123 | How AI is driving improved clinical, patient, and economic outcomes 27:26

1M ago27:26

27:26

In this episode of AI For Pharma Growth, Dr. Andree Bates talks to Dr Andrew Rut, CEO of Metadvice, about how AI is at the forefront of improvements to the pharmaceutical industry. Metadvice uses neural networks to enable clinicians to handle patients faster and with greater accuracy. It utilises both synthetic and real data to achieve an incredibl…

1
Genentech's oral weight loss drug shows promise; FDA denies accelerated approval for Agenus' cancer drug; Orexo's opioid overdose drug rejected again [The good, the bad, the ugly] 3:35

1M ago3:35

3:35

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Genentech's oral weight loss drug shows promise The bad — FDA denies accelerated approval for Agenus' cancer drug The ugly — Orexo's opioid overdose drug rejected again…

1
E122 | Encouraging AI Adoption in Teams 29:06

2M ago29:06

29:06

In this episode of AI For Pharma Growth, Dr. Andree Bates explores the pivotal role of AI in boosting team productivity within pharmaceutical companies, alongside Tim Cakir, CEO of TaskDrive. Tim's insights stem from his background as a growth consultant, driving TaskDrive's evolution towards AI-augmented virtual assistants and achieving remarkable…

1
Golden Innovations: Nanocrystal Therapies for ALS and MS with Clene Nanomedicines’ Dr. Karen Ho 34:11

28d ago34:11

34:11

In this episode, Ayesha spoke with Karen S. Ho, PhD, Vice President, Translational Medicine at Clene Nanomedicine, a biopharmaceutical company focused on developing treatments for neurodegenerative diseases to restore and protect neuronal health and function. Clene Nanomedicine is developing nanotherapeutics that target cellular energy impairments …

1
Pfizer advances obesity pill, FDA rejects Novo insulin, FTC releases PBM report [The good, the bad, the ugly] 3:28

2M ago3:28

3:28

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Pfizer advances once-daily obesity pill The bad — FDA rejects Novo Nordisk once-weekly insulin The ugly — FTC releases long-awaited report on PBMsBy Pharma Manufacturing

1
From Symptoms to Solutions: Transforming Menopause Treatment with Marci English of Astellas Pharma 28:17

1M ago28:17

28:17

In this episode, Ayesha spoke with Marci English, Vice President and Head of BioPharma Development at Astellas Pharma about a groundbreaking new treatment that addresses the underlying mechanisms of menopause symptoms. In May 2023, Astellas received FDA approval for fezolinetant (commercial name Veozah) for the treatment of moderate to severe vasom…

1
E121 | Predicting The Future With AI 36:14

1M ago36:14

36:14

In this episode, Dr. Andree Bates speaks with Jordan Miller, Founder of Satori, an open-source, decentralised AI prediction network. The project integrates AI and machine learning to enhance predictive capabilities. Jordan has spent the last decade building a worldwide prediction AI network and the past two years bringing it to life. His career as …

1
The Increasing Reliance on Digital Twins in the Built Environment 21:37

2M ago21:37

21:37

Marc Goldman, Director of Industry Solutions at Esri and Chair of DTC's AECO Working Group, chats with Bill Hoffman, Chairman & CEO of Object Management Group, about the growing use of digital twins in Architecture, Engineering, and Construction. Visit us at https://www.digitaltwinconsortium.org/By digitaltwinconsortium

1
Lilly Alzheimer’s drug gets full approval, Rocket gene therapy rejected, Eisai, BMS end ADC partnership [The good, the bad, the ugly] 3:44

2M ago3:44

3:44

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA grants Eli Lilly Alzheimer’s drug full approval The bad — FDA rejects Rocket gene therapy The ugly — Eisai, BMS end ADC partnershipBy Pharma Manufacturing

1
[Solutions Spotlight] Streamlining oral dose packaging design 31:57

2M ago31:57

31:57

By integrating a Quality by Design (QbD) approach, developers can design robust packaging from the outset, drastically reducing development time and costs. Understanding how moisture affects a product is key, allowing developers to use industry-accepted and validated models to predict and address potential stability issues early in the design phase…

1
New Frontiers in MASH and Chronic Liver Diseases with Aligos CEO Dr. Lawrence Blatt 34:59

1M ago34:59

34:59

In this episode, Ayesha spoke with Lawrence Blatt, PhD, MBA, Chairman and CEO of Aligos Therapeutics, a company developing targeted therapies for liver diseases like MASH (metabolic dysfunction-associated steatohepatitis) and viral diseases to address important unmet medical needs. Prior to co-founding Aligos Therapeutics, Dr. Blatt served as the G…

1
E120 | Can Healthcare Be Made More Accessible and Affordable Through Innovation & Disruptive Thinking? 34:57

2M ago34:57

34:57

In this episode, Dr. Andree Bates speaks with Professor Shafi Ahmed and discusses how innovation and disruptive thinking can transform healthcare, making it more accessible and affordable for everyone. Professor Shafi Ahmed is a renowned surgeon and co-founder of Medical Realities, a company pioneering the use of virtual and augmented reality in me…

1
Verona wins COPD nod, FDA rejects Merck-Daiichi ADC, Glenmark recalls potassium chloride capsules [The good, the bad, the ugly] 3:42

2M ago3:42

3:42

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Verona wins FDA nod for COPD The bad — FDA issues CRL to Merck-Daiichi lung cancer ADC The ugly — Glenmark recalls 114 batches of potassium chloride capsules…

1
Pharma Matters Podcast: Contract Pharma Talks with Tom Wilson of Pfizer CentreOne 29:59

2M ago29:59

29:59

Vice President and Global Contract Manufacturing Leader for Pfizer CentreOne talks about supply chain reliability trends.By Tom

1
FNIH’s Dr. Travaglia and ALS Patient Advocate Dr. Sethi Discuss New ALS Program 30:10

2M ago30:10

30:10

In this episode, Ayesha spoke with Alessio Travaglia, PhD, Director Neuroscience at the Foundation for the National Institutes of Health (FNIH) who also manages FNIH’s new Accelerating Medicines Partnership in Amyotrophic Lateral Sclerosis (AMP ALS) program, and Nadia Sethi, DDS, an ALS patient advocate who formerly served as Director of Community …

1
E119 | How to use AI for Visual Inspection and Traceability in Pharma Manufacturing 30:13

2M ago30:13

30:13

In this episode, Dr. Andree Bates speaks with Tristan Salomon, Founder and CEO of Axom, a company specialising in advanced AI solutions for the pharmaceutical industry. Tristan Salomon has a rich background in developing and implementing AI technologies to enhance manufacturing processes. His expertise lies in creating innovative solutions that imp…

1
Gilead HIV shot delivers zero infections, Takeda epilepsy drug misses endpoints, Lilly goes after counterfeiters [The good, the bad, the ugly] 3:36

2M ago3:36

3:36

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Gilead twice-yearly HIV shot delivers zero infections in trial The bad — Takeda epilepsy drug misses endpoints in trials The ugly — Eli Lilly goes after counterfeiters…

1
The Road Ahead for Former ALS Hopeful Relyvrio ft. Amylyx's Joshua Cohen and Justin Klee 41:04

2M ago41:04

41:04

In this episode, Ayesha spoke with Joshua Cohen and Justin Klee, co-CEOs and co-founders of Amylyx Pharmaceuticals, a company developing therapeutics for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). Josh and Justin co-founded Amylyx Pharmaceuticals in 2013. Josh co-invented the oral, fixed-dose combination AMX0035 (known com…

1
E118 | How To Use AI To Prevent Health Issues In Under Two Minutes 24:47

2M ago24:47

24:47

In this episode, Dr. Andree Bates speaks with Johannes Kraus, Co-Founder of YOUTH HealthTech. As a former physical therapist Johannes experienced patients suffering and approaching him every day, barely able to treat their diseases without the ability to properly follow their prevention. He founded YOUTH to prevent diseases by focusing on early det…

1
FDA backs Lilly Alzheimer’s drug; Pfizer Duchenne gene therapy fails; Talc plaintiffs seek J&J bankruptcy restraining order [The good, the bad, the ugly] 4:25

2M ago4:25

4:25

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA AdComm backs Eli Lilly Alzheimer’s drug The bad — Pfizer gene therapy fails phase 3 Duchenne trial The ugly — Talc plaintiffs seek restraining order on J&J bankruptcy tactic…

1
Staying Ahead of Cyber Adversaries with Digital Twins 19:16

3M ago19:16

19:16

Intuitus's David Shaw, co-chair of the DTC's Security & Trustworthiness working group, chats about digital twins and cybersecurity with Bill Hoffman, Object Management Group Chairman & CEO. Visit us at https:://www.digitaltwinconsortium.org/ .By digitaltwinconsortium

1
Insights into Precision Dosing with Dr. Howard McLeod and Dr. Sharmeen Roy 38:33

2M ago38:33

38:33

In this episode, Ayesha spoke with Howard McLeod, PharmD, Director of the Center for Precision Medicine and Functional Genomics, Professor of Pharmacy and Medicine at Utah Tech University and Precision Medicine Advisor at the Geriatric Oncology Consortium; and Sharmeen Roy, PharmD, Chief Strategy and Science Officer at DoseMe, which is the world’s …

1
E117 | Bringing The Human Body Into The Digital World 34:15

3M ago34:15

34:15

Today Dr Andree Bates chats with Dr Giulio Rognini, Head of Partnerships at Metaphysiks, about how Metaphysiks is revolutionising the world of haptic feedback. Metaphysiks is leading the charge in blending human sensation with the digital realm through their innovative neuro-haptic technology. They’ve even developed the world’s first proprietary ne…

1
AZ's Tagrisso shines in phase 3 trial, BMS layoffs, FDA violations at Jiangsu Hengrui site [The good, the bad, the ugly] 3:44

3M ago3:44

3:44

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — AstraZeneca’s Tagrisso delivers 84% progression-free survival in trial The bad — BMS to let go of 863 employees at NJ site The ugly — FDA inspection uncovers multiple violations at Jiangsu Hengrui Ph…

1
Quick Hits: Rocky Mountain Highlights - Cain Brothers’ Inaugural MedTech & Life Sciences Summit 10:59

3M ago10:59

10:59

In this Quick Hits House Call, Dave talks to Cain Brothers’ Managing Director and Head of M&A John Soden about the recent MedTech and Life Sciences CEO Summit he hosted in Aspen, Colorado which brought innovative leaders together to discuss the complex challenges they’re facing today. Cain Brothers is a division of KeyBanc Capital Markets.…

1
Targeting AML with a New Generation of T-Cell Therapies, ft. Brian Atwood, Chairman and CEO of CERo Therapeutics 29:39

2M ago29:39

29:39

In this episode, Ayesha spoke with Brian Atwood, Chairman and CEO of CERo Therapeutics, a company pioneering a new generation of autologous T-cell-based therapies for both hematologic and solid tumor cancers. Prior to joining CERo, Brian Atwood served as Chairman of the board of directors of Phoenix Biotech Acquisition Corp., which merged with CERo…

1
Episode 11: A View On the History of Capsule Manufacturing 28:18

3M ago28:18

28:18

Tracing the Evolution and Future of Capsule Manufacturing In this episode, we are joined by Ljiljana Palangetic, Associate Director of Hard Capsules R&D, and Bram Baert, Senior Director of Regulatory Affairs from Lonza, to delve into the intricacies of capsule manufacturing and the evolution of drug delivery technologies. Your grandmother might hav…

1
E116 | How AI Is Unlocking Multi-Omics Data 22:16

3M ago22:16

22:16

In this episode of AI For Pharma Growth, Dr. Andree Bates is joined by Abishek Jha, Co-Founder and CEO of Elucidata, which cleans and links biomedical data at scale. They advocate for a data-centric approach to AI, arguing that clean data is more valuable than copious data. In this episode, you will learn: How Elucidata’s sources and processes data…

1
J&J depression drug aces trial, Takeda plans layoffs, FDA delays review of Sanofi-Regeneron's Dupixent [The good, the bad, the ugly] 3:24

3M ago3:24

3:24

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — J&J depression drug aces late-stage trial The bad — Takeda plans layoffs at Massachusetts sites The ugly — FDA delays review of Sanofi-Regeneron's Dupixent in COPD…

Podcasts Worth a Listen

Pharma Manufacturing Podcasts

Podcasts Worth a Listen

Quick Reference Guide